KAMADA LTD
No enriched coverage for $KMDA in the last 7 days.
No SEC Form 4 filings for $KMDA in the last 30 days.
Kamada (KMDA) reported strong FY25 revenue growth and increased net income, despite missing Q4 consensus estimates. Management reaffirmed robust 2026 guidance and announced a new annual dividend policy, signaling confidence in future growth. The company trades at a discounted valuation, with biosimilars expansion and a strong balance sheet supporting its investment appeal.
Kamada's shares saw a decline following the announcement that the company has halted its Phase 3 study of an inhaled Alpha-1 Antitrypsin (AAT) therapy. The decision to stop the clinical trial is a significant setback for the development of this particular AAT treatment.
Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited ( "Advanz Pharma" ) , a UK headquartered global pharmaceutical company with a strategic focus on specialty, ...
